# Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer

> **NCT02896803** · PHASE2 · UNKNOWN · sponsor: **Instituto do Cancer do Estado de São Paulo** · enrollment: 37 (estimated)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** mFLOX

## Key facts

- **NCT ID:** NCT02896803
- **Lead sponsor:** Instituto do Cancer do Estado de São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2021-07
- **Final completion:** 2021-12
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2020-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02896803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02896803, "Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02896803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*